NLSP — NLS Pharmaceutics AG Share Price
Last trade - 00:00- $8.68m
- $9.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.
Directors
- Ronald Hafner NEC (57)
- Alexander Zwyer CEO (51)
- Subhasis Roy CFO (52)
- Silvia Panigone COO (49)
- Eric Konofal CSO (54)
- Carlos Camozzi OTH (68)
- Myoung-Ok Kwon IND (50)
- Stig Pedersen IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 5th, 2015
- Public Since
- January 29th, 2021
- No. of Shareholders
- 24
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 39,563,249
- Address
- The Circle 6, ZUERICH, 8058
- Web
- https://nlspharma.com/
- Phone
- +41 445122150
- Auditors
- PricewaterhouseCoopers AG
Latest News for NLSP
Upcoming Events for NLSP
Similar to NLSP
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 22:21 UTC, shares in NLS Pharmaceutics AG are trading at $0.19. This share price information is delayed by 15 minutes.
Shares in NLS Pharmaceutics AG last closed at $0.19 and the price had moved by -81.75% over the past 365 days. In terms of relative price strength the NLS Pharmaceutics AG share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for NLS Pharmaceutics AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.
NLS Pharmaceutics AG does not currently pay a dividend.
NLS Pharmaceutics AG does not currently pay a dividend.
NLS Pharmaceutics AG does not currently pay a dividend.
To buy shares in NLS Pharmaceutics AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.19, shares in NLS Pharmaceutics AG had a market capitalisation of $7.44m.
Here are the trading details for NLS Pharmaceutics AG:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NLSP
Based on an overall assessment of its quality, value and momentum NLS Pharmaceutics AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in NLS Pharmaceutics AG is $6.00. That is 3091.49% above the last closing price of $0.19.
Analysts covering NLS Pharmaceutics AG currently have a consensus Earnings Per Share (EPS) forecast of -$0.45 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NLS Pharmaceutics AG. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $0.19, shares in NLS Pharmaceutics AG were trading -55.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The NLS Pharmaceutics AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
NLS Pharmaceutics AG's management team is headed by:
- Ronald Hafner - NEC
- Alexander Zwyer - CEO
- Subhasis Roy - CFO
- Silvia Panigone - COO
- Eric Konofal - CSO
- Carlos Camozzi - OTH
- Myoung-Ok Kwon - IND
- Stig Pedersen - IND